View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
June 8, 2020

Indian Health Ministry issues draft rules for new Covid-19 drugs

The Indian Health Ministry has issued a draft notification for ‘compassionate use’ of any unapproved drug that is in the Phase III clinical trial across the globe.

The Indian Health Ministry has issued a draft notification for ‘compassionate use’ of any unapproved drug that is in the Phase III clinical trial across the globe.

The draft New Drugs and Clinical Trials (Amendment) Rules seek to facilitate the availability of experimental drugs for severely ill Covid-19 patients.

A gazette notification of the draft rules was published in this regard.

According to the notification, a hospital or medical institution may import new drugs for ‘compassionate use for treatment of patients suffering from life threatening disease or disease causing serious permanent disability or disease requiring therapy for unmet medical need,’ PTI reported.

Additionally, any new drug prescribed by a hospital for the same purposes may be approved and can be manufactured in limited quantity. This is subject to provisions of the rules.

These new rules have been inserted under section 96, which deals with filing an application and issues the license to the importer or manufacturer. The licence will remain valid for one year for manufacturing and importing, from the date it has been issued.

In the case where an importer or manufacturer who gets the license does not comply with any provision of the act and these rules, their license can be suspended or cancelled by the Central Licencing Authority.

The new draft rules will be applicable for a period of 15 days. During this time, people will be able to send their objections and suggestions which will be considered by the central government.

Later on, the final amended rules will be published in the gazette of India.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena